Pharmacogenetics and cancer management

Pharmacogenetics and Pain Management

More recently, 2 non-cytochrome P450 “pharmacodynamic” genetic tests have been identified that help explain opioid dosage requirements in pain patients. The first measures, opioid mu receptor 1 (OPRM1), which determines the ability of opioids to bind to the mu opioid receptor site. The other measures catechol-o methyltransferase (COMT), the enzyme that degrades catecholamines in the central ner...

pharmacogenetics and personalized medicine in pancreatic cancer

pancreatic cancer (pc) is a progressive, fatal disease with a high degree of malignancy. more than 40000 peoplediefrom this cancer annually in the united states. as a multifactorial condition, pc has a complex nature, and there are several genes and signalingpathwaysimplicated in pc pathogenesis and progression. there are diffèrent mutations in master genesincludingtumorsuppressors and oncogene...

Pharmacogenetics in pancreatic cancer.

Pancreatic cancer is an aggressive malignancy with a poor overall survival rate. Given advances in pharmacogenomics, numerous gene mutations have been identified that could be potential targets for drug development. Therefore, future research strategies may identify prognostic and predictive markers aiming to improve outcome by maximizing efficacy whilst lowering toxicity. In this commentary, w...

Pharmacogenetics of breast cancer therapies.

Treatment decisions for breast cancer patients are currently based on a small number of crude predictive markers, despite the known complexity and heterogeneity of the disease. The field of pharmacogenetics can increase the precision with which therapeutic decisions are made. Discovering associations between genetic variation and treatment response will allow clinicians to tailor therapies to m...

Pharmacogenetics of Cancer and DNA Repair Enzymes